DARU-JOURNAL OF FACULTY OF PHARMACY (DARU )

Publisher: Dānishgāh-i ʻUlūm-i Pizishkī-i Tihrān. Dānishkadah-ʼi Dārūʹsazī; SPARC (Organization)

Description

Daru is a Persian name, meaning drug. Daru has been published in Persian from 1991 to 1995,in Persian with English abstract from 1995 to 1999 and only in English language form the early of 1999 four times a year. The main scope of this journal is to publish original research articles in pharmaceutical sciences. Editorial board of DARU are specialist in different areas of pharmacy. All submitted manuscripts are initially evaluated in the editorial meeting (regularly is held every two weeks) to determine peer reviewers in the related subjects. On the basis of reviewer's comments, the editorial committee decide about the acceptance or rejection of the submitted manuscript and in the case that the manuscript is acceptable, the main author will be asked to revise it according to the reviewer's comments or reply to their questions and comments. Final decision about acceptance of a manuscript for publication in DARU will be made in the editorial board meeting on the basis of reviewer's comments, author's responses or revisions. Outstanding basic and applied papers, reviews, short communication, and notes in the pharmaceutical and biomedical fields especially pharmaceutical and biomedical analyses, chemistry & medicinal chemistry, medical biotechnology, pharmaceutics, pharmacognosy & natural products, toxicology & pharmacology, clinical pharmacy & pharmacotherapy, quality control of foods and drugs, social aspects of pharmacy, and drug design are welcome. It is believed that there are only a few international journals that have the same general scope as DARU has. Scientists and academicians in the field of drug-related matters could be audience of this journal.

  • Impact factor
    0.62
    Show impact factor history
     
    Impact factor
  • 5-year impact
    0.71
  • Cited half-life
    4.70
  • Immediacy index
    0.15
  • Eigenfactor
    0.00
  • Article influence
    0.11
  • Website
    Daru website
  • Other titles
    Daru (Online), Journal of Faculty of Pharmacy, Tehran University of Medical Sciences
  • ISSN
    1560-8115
  • OCLC
    61283828
  • Material type
    Document, Periodical, Internet resource
  • Document type
    Internet Resource, Computer File, Journal / Magazine / Newspaper

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Sepsis complication is a major cause of death in multiple trauma critically ill patients. Defensin (cysteine rich anti-microbial peptides), as an important component of immune system, might play an important role in this process. There is also rising data on immunological effects of N-acetyl-cysteine (NAC), a commonly used anti-oxidant in oxidative stress conditions and glutathione (GSH) deficiencies. The aim of the present study was to evaluate the potential beneficial effects of NAC administration on multiple trauma patients with sepsis. Methods In a prospective, randomized controlled study, 44 multiple trauma critically ill patients who were mechanically ventilated and met the criteria of sepsis and admitted to the intensive care unit (ICU) were randomized into two groups . Control group received all standard ICU therapies and NAC group received intravenous NAC 3 gr every 6 hours for 72 hours in addition to standard therapies. Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, length of ICU stay, ICU mortality were recorded. Levels of serum Immunoglobulin M (IgM), Human beta-Defensin 2 (HbetaD2) and GSH were assessed at baseline and 24, 72, 120 hours after intervention. Results During a period of 13-month screening, 44 patients underwent randomization but 5 patients had to be excluded. 21 patients in NAC group and 18 patients in control group completed the study. For both groups the length of ICU stay, SOFA score and systemic oxygenation were similar. Mortality rate (40% vs. 22% respectively, p = 0.209) and ventilator days (Mean +/- SD 19.82 +/- 19.55 days vs. 13.82 +/- 11.89 days respectively, p = 0.266) were slightly higher for NAC group. IgM and GSH levels were similar between two groups (p = 0.325, 0.125 respectively), HbetaD2 levels were higher for NAC group (at day 3). Conclusion High dose of NAC administration not only did not improve patients ' outcome, but also raised the risk of inflammation and was associated with increased serum creatinine.
    DARU-JOURNAL OF FACULTY OF PHARMACY 07/2014; 22(57).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuroinflammation and oxidative stress has been shown to be associated with the development of Parkinson disease (PD). In the present study, we investigated the effect of intraperitoneal (i.p) administration of silymarin, on 6-OHDA-induced motor-impairment, brain lipid per-oxidation and cerebrospinal fluid (CSF) levels of inflammatory cytokine in the rats. The results showed that silymarin is able to improve motor coordination significantly (p < 0.001) in a dose dependent manner. There was a significant (p < 0.001) increase in MDA levels of 6-OHDA-lesioned rats whereas; in silymarin (100, 200 and 300 mg/kg, i.p. for 5 days) pre-treated hemi-parkinsonian rats MDA levels was decreased markedly (p < 0.001). Furthermore the CSF levels of IL-1beta was decreased (p < 0.001) in silymarin (100, 200 and 300 mg/kg) pre-treated rats up to the range of normal non-parkinsonian animals. We found that pre-treatment with silymarin could improve 6-OHDA-induced motor imbalance by attenuating brain lipid per-oxidation as well as CSF level of IL-1beta as a pro-inflammatory cytokine. We suggest a potential prophylactic effect for silymarin in PD. However, further clinical trial studies should be carried out to prove this hypothesis.
    DARU-JOURNAL OF FACULTY OF PHARMACY 04/2014; 22(1):38.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Selective delivery of anticancer agents to target areas in the body is desirable to minimize the side effects while maximizing the therapeutic efficacy. Anthracycline antibiotics such as doxorubicin (DOX) are widely used for treatment of a wide variety of solid tumors.This study evaluated the potential of a polymeric micellar formulation of doxorubicin as a nanocarrier system for targeted therapy of a folate-receptor positive human ovarian cancer cell in line. DOX-conjugated targeting and non-targeting micelles prepared by the dialysis method were about 188 and 182 nm in diameter, respectively and their critical micelle concentration was 9.55 mug/ ml. The DOX-conjugated micelles exhibited a potent cytotoxicity against SKOV3 human ovarian cancer cells. Moreover, the targeting micelles showed higher cytotoxicity than that of non-targeting ones (IC50 = 4.65 mug/ml vs 13.51 mug/ml). The prepared micelle is expected to increase the efficacy of DOX against cancer cells and reduce its side effects.
    DARU-JOURNAL OF FACULTY OF PHARMACY 03/2014; 22(1):30.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tramadol is an opioid, synthetic analog of codeine and has been used for the treatment of acute or chronic pain may be abused. In this work, a developed Dispersive liquid liquid microextraction (DLLME) as binary solvents-based dispersive liquid-liquid microextraction (BS-DLLME) combined with high performance liquid chromatography (HPLC) with fluorescence detection (FD) was employed for determination of tramadol in the urine samples. This procedure involves the use of an appropriate mixture of binary extraction solvents(70 muL CHCl3 and 30 muL ethyl acetate) and disperser solvent (600 muL acetone) for theformation of cloudy solution in 5 ml urine sample comprising tramadol and NaCl (7.5%, w/v). After centrifuging, the small droplets of extraction solvents were precipitated. In the final step, the HPLC with fluorescence detection was used for determination of tramadol in the precipitated phase. Various factors on the efficiency of the proposed procedure were investigated and optimized. The detection limit (S/N = 3) and quantification limit (S/N = 10) were found 0.2 and 0.9 mug/L, respectively. The relative standard deviations (RSD) for the extraction of 30 mug L of tramadol was found4.1% (n = 6). The relative recoveries of tramadol from urine samples at spiking levels of 10, 30and60 mug/L were in the range of 95.6 - 99.6%. The relative recoveries of tramadol from urine samples at spiking levels of 10, 30, 60 mug/ L were in the range of95.6 - 99.6%. Compared with other methods, this method provides good figures of merit such as good repeatability, high extraction efficiency, short analysis time, simple procedure and can be used as microextraction technique for routine analysis in clinical laboratories.
    DARU-JOURNAL OF FACULTY OF PHARMACY 02/2014; 22(1):25.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The deposition of amyloid peptides is associated with Alzheimer's disease (AD). These amyloid peptides are derived from the amyloid protein precursor (APP). Silymarin, a standardized extract of milk thistle, which is currently used in liver diseases, may be effective in the inhibition of amyloid formation. However, its effect has not been assessed on APP expression. In this study, first, the effect of silymarin was examined on the passive avoidance learning in a rat model of AD. This model was induced by the intracerebroventricular injection of Abeta peptide (Abeta1-42) in Wistar rats. Rats were treated with 70 and 140 mg/kgof the extract, once a day, for 4 weeks. Memory function that was evaluated in a shuttle-cage test, showed improvement upon administration of this extract. Brain amyloid plaques had also decreased upon administration of the extract. Furthermore, APP gene expression was compared in treated and untreated groups. The result showed that silymarin was able to suppress APP expression. Our results are in accordance with the in vitro tests concerning the positive antiamyloidogenic property of the main component of silymarin, namely silibinin. We suggest that the beneficial effect of sylimarin in the AD model is related to its capacity to disaggregate amyloid plaques and to suppress APP expression. Considering the limited side effects of silymarin, this compound could be of use in AD therapy.
    DARU-JOURNAL OF FACULTY OF PHARMACY 01/2014; 22(1):24.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of the study: Comparative in vitro studies were carried out to determine the adsorption characteristics of 3 drugs on activated charcoal (AC) and sodium polystyrene sulfonate (SPS). Activated charcoal (AC) has been long used as gastric decontamination agent for tricyclic antidepressants (TCA). Solutions containing drugs (amitriptyline, clomipramine, or doxepin) and variable amount of AC or SPS were incubated for 30 minutes. At pH 1.2 the adsorbent: drug mass ratio varied from 2 : 1 to 40 : 1 for AC, and from 0.4 : 1 to 8 : 1 for SPS. UV-VIS spectrophotometer was used for the determination of free drug concentrations. The qmax of amitriptyline was 0.055 mg/mg AC and 0.574 mg/mg SPS, qmax of clomipramine was 0.053 mg/mg AC and 0.572 mg/mg SPS, and qmax of doxepin was 0.045 mg/mg AC and 0.556 mg/mg SPS. The results of adsorption experiments with SPS revealed higher values for the qmax parameters in comparison with AC. In vitro gastric decontamination experiments for antidepressant amitriptyline, clomipramine, and doxepin showed that SPS has higher qmax values than the corresponding experiments with AC. Therefore, we suggest SPS is a better gastric decontaminating agent for the management of acute TCA intoxication.
    DARU-JOURNAL OF FACULTY OF PHARMACY 01/2014; 22(1):21.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A case with reversible symmetrical sensorineural hearing loss following hydroxychloroquine therapy is described.Case summary: A 57-year-old, human immunodeficiency virus (HIV) positive man was referred to the HIV clinic of Imam Khomeini Hospital, Tehran with chief complaint of bilateral slowly progressive hearing loss starting from two months ago. The man had history of rheumatoid arthritis diagnosed from 3 months ago and was administered hydroxychloroquine 200 mg and prednisolone 5 mg twice daily. Audiometry test showed moderate to severe neuronal hearing loss and reduced speech recognition in both ears of the patient. With suspicion of hydroxychloroquine-induced hearing loss, this drug was discontinued. After 2 months of hydroxychloroquine discontinuation, his audiometry findings were improved. A few cases of hydroxychloroquine-induced hearing loss have been reported. All of the cases were non-HIV positive individuals. Irreversible hearing loss was developed following long-term therapy with hydroxychloroquine. The present case was a HIV-positive man who developed hearing loss following short course (one month) hydroxychloroquine therapy and his problem was resolved following discontinuation of hydroxychloroquine and continuation of prednisolone. Hydroxychloroquine-induced hearing loss may reversibly occur following short term therapy in HIV patients.
    DARU-JOURNAL OF FACULTY OF PHARMACY 01/2014; 22(1):20.